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This review summarizes 11 major clinical research advances in gynecologic oncology in 2010. For ovarian cancer, 
bevacizumab as a leading molecular targeted agent, pegylated liposomal doxorubicin in recurrent disease, the role of 
neoadjuvant chemotherapy in an advanced setting, an effective screening method, and ARID1A mutations as a clue to 
the origin of clear cell carcinoma are mentioned. For cervical cancer, confirmation of the efficacy and the introduction 
of a self collection method of the human papillomavirus (HPV) test, and the association between the HPV vaccine and 
miscarriage are examined. For endometrial cancer, the superiority of laparoscopy in staging operation, the role of 
vaginal brachytherapy in an adjuvant setting, and the effect of para-aortic lymph node dissection are reviewed. In 
addition, the trend of geriatric oncology and chemotherapy in carcinosarcomas is also assessed.
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INTRODUCTION
The most outstanding advances in the field of gynecologic 
oncology in 2010 were not groundbreaking discoveries of 
brand-new concepts of management, but the final or interim 
results of existing studies. Extensive research has been being 
carried out into bevacizumab (BEV), which is currently one of 
the most promising targeted agents and the best combination 
of the conventional chemotherapeutic agents.
Similar to last year,1 the major journals were searched for 
these topics. The abstracts that were presented at the Society 
of Gynecologic Oncologists (SGO) Annual Meeting, the 
American Society of Clinical Oncology (ASCO), the European 
Society for Medical Oncology (ESMO) Annual Congress, and 
the International Gynecologic Cancer Society (IGCS) Biennial 
Meeting were reviewed for the publication of influential 
randomized clinical trials. 
In addition, we referred to online news such as USAtoday 
(www.usatoday.com/news/health) and Time (www.time. 
com/time/health), which provided some indications when 
the topic of ovarian cancer screening was chosen. Finally, geri-
atric oncology was also selected as a topic of this review be-
cause it is expected to become increasingly important with the 
rapid growth of the elderly population, even though there 
were no major publications or presentations in the field of 
geriatric oncology in 2010.
This review not only summarizes the remarkable research 
achievements in gynecologic cancer in 2010, but also pro-
poses a direction of research in the future.
MAJOR CLINICAL RESEARCH ADVANCES
1. Bevacizumab, the leading molecular targeted agent for 
ovarian cancer
Several phase III randomized controlled trials (RCTs) in ovar-
ian cancer have been carried out since phase II trials demon-
strated the activity of BEV as a single agent and in combination 
with other modalities, such as low-dose metronomic cyclo-
phosphamide.2-5 Among them, two key first-line studies, 
Gynecologic Oncology Group (GOG) 218 and International 
Collaborative Ovarian Neoplasm (ICON) 7, reported their pre-
liminary findings at the 2010 ASCO Annual Meeting (abstract 
LBA1) and the 35th ESMO Congress (abstract LBA4), respec-
tively.6,7
GOG 218 is a study of 1,873 patients. The control group 
(arm I, n=625) received the standard treatment with 6 cycles 
of carboplatin (AUC 6) and paclitaxel (175 mg/m2). There 
were two experimental groups, one (arm II, n=625) received 
BEV (15 mg/kg every 3 weeks) only during the same chemo-
therapy, switching to three-weekly placebo infusions for 1 
year, which was also administered throughout treatment in 
the control group. The second group (arm III, n=623) re-
ceived BEV during chemotherapy and for a further 16 cycles of 
maintenance, leading to a total of 16 months of therapy. The 
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patients included those who had undergone maximal debulk-
ing surgery: stage III optimal (macroscopic residual disease ≤
1 cm) or suboptimal (＞1 cm), or stage IV epithelial ovarian 
(EOC), primary peritoneal (PPC) or fallopian tube cancer 
(FTC), without prior chemotherapy. GOG 218 met the pri-
mary objective as the front-line treatment of advanced ovarian 
cancer. The progression free survival (PFS) with paclitax-
el/carboplatin plus BEV followed by BEV maintenance (arm 
III) was significantly superior to that of paclitaxel/carboplatin 
alone (arm I) (hazard ratio [HR], 0.717; 95% confidence in-
terval [CI], 0.625 to 0.824; p＜0.0001), but PFS with paclitax-
el/carboplatin plus BEV without maintenance (arm II) was 
not (HR, 0.908; 95% CI, 0.759 to 1.040; p=0.080). The lim-
ited overall survival (OS) analysis at the time of the final PFS 
analysis failed to show any OS improvement both in arms II 
(HR, 1.036; 95% CI, 0.827 to 1.297; p=0.361) and III (HR, 
0.915; 95% CI, 0.727 to 1.152; p=0.252).8
In ICON 7, the eligible patients were 1,528 women with 
high-risk early (stage I or IIA, grade 3 or clear cell histology ≤
10%) or advanced (stage IIB-IV) EOC, PPC or FTC. The pa-
tients were randomized to either 6 cycles of 3 weekly carbo-
platin (AUC 6) and paclitaxel (175 mg/m2) alone (control 
group, n=764), or to the same chemotherapy with BEV (7.5 
mg/kg) for 6 cycles followed by maintenance BEV for an addi-
tional 12 cycles every 3 weeks or until progression, whichever 
came first (research group, n=764). The research group 
showed a longer PFS than the control group (HR, 0.81; 95% 
CI, 0.70 to 0.94; p=0.0041). Preliminary OS data revealed 
1-year survival rates of 93% and 95% in the control and ex-
perimental group, respectively (HR, 0.81; 95% CI, 0.63 to 
1.04; p=0.098), even though longer term PFS and mature OS 
results are anticipated in 2012.
In both studies, adverse events were consistent with pre-
vious BEV studies and the treatment was well tolerated with 
no new safety concerns.2,4,9 Despite the difference in the stage 
composition in the eligible criteria and dose of BEV, GOG 
218, and ICON 7 reported comparable PFS and preliminary 
OS results. The treatment effects in ICON 7 were numerically 
greater in the advanced-stage (stage III suboptimal and stage 
IV with debulking) patients (HR, 0.68; 95% CI, 0.55 to 0.85; 
p＜0.001). Although the long term OS, quality of life, and oth-
er translational research results are soon to be released, pa-
tients diagnosed with an advanced stage are expected to re-
ceive substantial benefit from the addition of BEV. 
Another BEV study in recurrent ovarian cancer, GOG 213, is 
also underway. This study is a phase III RCT of paclitaxel/car-
boplatin alone or in combination with BEV followed by BEV 
and secondary cytoreductive surgery in platinum-sensitive, 
recurrent ovarian cancer, PPC and FTC. Over the next 3-4 
years, the results of several BEV trials including GOG 213 will 
follow.5 Regardless of whether the results are positive or not, 
the pending problem currently faced is the identification of bi-
omarkers that can be used to select patients for BEV. This will 
assist in the decision regarding the indication and best sched-
ule for BEV therapy.
2. Best chemotherapeutic regimen in recurrent ovarian 
cancer 
Platinum is the basis of treatment, and paclitaxel/carboplatin 
have emerged as a standard in a first-line setting and as a re-
challenge for patients with platinum-sensitive recurrent ovarian 
cancer,10-13 even though the prognosis of ovarian cancer remains 
poor. Many different second-line regimens, as a single or a com-
bination, have been being tested for their efficacy and toxicity 
in RCTs with the aim of improving the prognosis of recurrent 
ovarian cancer. The regimen that has shown at least non-inferior 
activity and has been approved by the US Food and Drug 
Administration (FDA) include platinum compounds, paclitax-
el, pegylated liposomal doxorubicin (PLD), altretamine, and 
topotecan.12,14-20
Among them, PLD has been demonstrated to be superior to 
topotecan/gemcitabine in trials in second-line settings.21-23 In 
2010, there was notable progress in studies with PLD/tra-
bectedin with various combinations in recurrent ovarian 
cancer. Caelyx in Platinum Sensitive Ovarian (CALYPSO) pa-
tients the largest phase III RCT in recurrent ovarian cancer, 
was designed to test the efficacy and safety of a combination 
of PLD (30 mg/m2) with carboplatin (AUC 5) every 4 weeks, 
compared to standard paclitaxel (175 mg/m2)/carboplatin 
(AUC 5) every 3 weeks for at least 6 cycles in patients with a 
platinum-sensitive recurrent ovarian cancer.24 The PFS for the 
PLD-carboplatin arm was superior to that of the paclitax-
el/carboplatin arm (HR, 0.821; 95% CI, 0.72 to 0.94; p= 
0.005) with the median PFS being 11.3 vs. 9.4 months. The 
PLD-carboplatin was associated with less severe toxicity than 
paclitaxel/carboplatin: hair loss (7% vs. 83.6%; p＜0.001), 
grade 2 or higher neuropathy (4.9% vs. 26.9%; p＜0.001), and 
carboplatin hypersensitivity reactions (5.6% vs. 18.8%; p
＜0.001). Therefore, PLD-carboplatin provides a more effec-
tive, less toxic alternative to the current standard for patients 
with platinum-sensitive recurrent ovarian cancer.
Systematic analysis of the peer-reviewed literature that com-
pared PLD/carboplatin with gemcitabine/carboplatin for pa-
tients with platinum-sensitive recurrent ovarian cancer also re-
ported a longer PFS and OS for the PLD/carboplatin regimen 
with better tolerability than gemcitabine/carboplatin. This 
suggests that PLD/carboplatin is a rational alternative to gem-
citabine/carboplatin for the treatment of patients with plati-
num-sensitive recurrent ovarian cancer.25
Monk et al.20 performed another influential study of the PLD 
in recurrent ovarian cancer, OVA-301, in which the patients 
were randomized to PLD alone (50 mg/m2) every 4 weeks, or 
PLD (30 mg/m2) followed by trabectedin (1.1 mg/m2) every 3 
weeks. The median PFS was 7.3 months with PLD/trabectedin 
vs. 5.8 months with PLD alone (HR, 0.79; 95% CI, 0.65 to 0.96; 
p= 0.0190). The PFS and the overall response rates of PLD/tra-
bectedin were superior to PLD alone, but only for plati-
num-sensitive patients, not for platinum-resistant patients. 
Major clinical research advances in gynecologic cancer in 2010
211
Although neutropenia was more common with PLD/trabecte-
din and the OS data was preliminary, this combination pro-
vided a new option for platinum-sensitive patients with re-
current ovarian cancer. 
After OVA-301, subgroup analysis was performed in the 
partially platinum-sensitive (platinum-free interval [PFI], 6 
to 12 months) subpopulation.26 Patients in the PLD/trabecte-
din arm received subsequent chemotherapy at a later time 
(median delay 2.5 months vs. PLD alone arm). A significantly 
prolonged OS from subsequent platinum was observed in this 
partially platinum-sensitive subset (HR, 0.63, p=0.0357; me-
dian 13.3 vs. 9.8 months). In addition, Kaye et al.27 suggested 
that the enhanced survival benefits in the partially plati-
num-sensitive subset might be due to the extended PFI lead-
ing to a longer survival with subsequent platinum, which was 
also presented in the 13th IGCS biennial meeting.
Because the OS advantage has not been proven, the PLD/tra-
bectedin may be an important option for patients with plati-
num-sensitive relapse who cannot tolerate platinum as a re-
sult of neuropathy or hypersensitivity. Otherwise platinum- 
based therapy should still be considered the treatment of 
choice in platinum-sensitive recurrent ovarian cancer.19 
3. Neoadjuvant chemotherapy in advanced ovarian cancer
After the preliminary data report of the first RCT directly ad-
dressing this issue at the 12th IGCS biennial meeting in 2008, 
the final analyses were published this year.28 A total of 670 pa-
tients with stage IIIc or IV were assigned randomly to primary 
debulking surgery followed by platinum-based chemotherapy 
or to neoadjuvant chemotherapy (NAC) followed by interval 
debulking. Optimal debulking (largest residual tumor ≤1 
cm) was achieved after primary and interval debulking sur-
gery in 41.6% and 80.6%, respectively. The postoperative ad-
verse effects and mortality were higher after primary debulk-
ing than after interval debulking. The OS and PFS were similar 
in both groups. Therefore, NAC followed by interval debulk-
ing may be a treatment option for patients with bulky stage 
IIIc or IV ovarian carcinoma. The authors also mentioned that 
a complete resection of all macroscopic disease (at primary 
debulking or interval surgery) was the strongest independent 
variable in predicting the OS. 
Recently, there has been growing consensus that optimal cy-
toreduction should no longer be defined as a residual tumor
＜1 or＜0.5 cm but as a resection without a macroscopic re-
sidual tumor.29,30 However, aggressive cytoreduction is not al-
ways feasible.31 In addition, a significant decrease in the OS 
was noted in the trial by Vergote et al.29 during the first 3 
months after randomization in patients undergoing primary 
debulking. This was most likely due to postoperative mortal-
ity and a delay in postoperative chemotherapy. These points 
that have prompted interest in NAC followed by interval de-
bulking as a primary treatment in advanced ovarian cancer.
Although this topic was already covered at the ‘Major Clini-
cal Research Advances in Gynecologic Cancer’ in 2008, there 
is a good reason to review it again because contrary to our ex-
pectations, the proven non-inferiority of NAC followed by in-
terval debulking does not appear to bring about a significant 
change in the clinical practice of ovarian cancer patients with 
stage IIIc and IV.29,31 In an interesting questionnaire on NAC 
in advanced ovarian cancer targeting SGO members,32 60% of 
respondents answered that they used NAC in less than 10% of 
their patients with advanced stage ovarian cancer. Most re-
spondents (82%) did not consider the available evidence suf-
ficient to justify NAC followed by interval debulking.29 This 
uncertain reluctance to adopt NAC as a standard treatment 
created some controversy at the 13th IGCS biennial meeting.
Dr. Vergote (Belgium) and Dr. Hoskins (Canada) were on 
the pro side, whereas Dr. Chi (USA) and Dr. du Bois (Ger-
many) had the alternative view. Dr. Chi mentioned the history 
of opposite results of trials from Europe and USA and con-
tinued to state that the different results might be caused by 
the different debulking rate and different efficacy of the che-
motherapy regimen used. From this point of view, he sug-
gested that the study by Vergote et al.29 is not enough to justi-
fy NAC, because there were several institutions where opti-
mal debulking rates were far below average. However, there is 
no evidence that an increased optimal debulking rate would 
negate the beneficial effects of NAC. Furthermore, because 
optimal debulking rates of most institutions are likely to be in 
the range of 30.6% to 71.0% (the range of optimal debulking 
rate in Vergote trial), we can accept the conclusion favoring 
NAC.
It is important to determine the indication of NAC. The main 
predictive factors of debulking surgery resulting in no residual 
macroscopic tumor, such as co-morbidities, age, disease bur-
den, location of metastatic sites, performance status, and 
stage, should be considered when deciding whether a patient 
is a candidate for primary debulking surgery or for NAC.29
4. Dual tests might permit ovarian cancer screening
The absence of both an effective screening method and early 
symptoms contributes to the poor prognosis of ovarian cancer. 
More than two thirds of ovarian cancers are diagnosed when 
the disease has progressed to stage III or IV.33 The 5-year sur-
vival rate is approximately 90% when ovarian cancer is de-
tected and treated while it is still confined to the ovary (stage 
I), which is in contrast to the rate of approximately 33% when 
the disease is diagnosed at stage III or IV.34 This is why ovarian 
cancer is called the ‘silent killer.’ 
Routine screening is not recommended by any professional 
groups, including US Preventive Services Task Force, American 
Cancer Society, American College of Obstetricians and Gyne-
cologists, and National Comprehensive Cancer Network.35-37 
It is not easy for investigators to develop a good screening test 
for ovarian cancer because it requires both high sensitivity and 
high specificity given the low prevalence of ovarian cancer, at 
least 75% sensitivity and 99.6% specificity to achieve a positive 
predictive value (PPV) of 10%, which is the minimum PPV set 
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by most epidemiologists to support a screening test.34
Of the two large RCTs that have completed the enrollment of 
patients, Prostate, Lung, Colon, and Ovarian (PLCO) Cancer 
Screening Trial,38 and the United Kingdom Collaborative Trial 
of Ovarian Cancer Screening (UKCTOCS),39 only the latter re-
ported promising preliminary findings last year. In UKCTOCS, 
202,638 postmenopausal women with an average risk for ovar-
ian cancer were assigned randomly to undergo an annual pelvic 
examination (control group), annual transvaginal ultrasono-
graphy (TVS) (USG group), or annual measurement of the CA- 
125 level (evaluated over time using the risk of ovarian cancer 
algorithm, ROCA) plus TVS in cases in which the CA-125 level 
was elevated (multimodality group).39 Surgery was performed 
less frequently in the multimodality group than in the USG 
group (0.2% vs. 1.8%). Of the invasive cancers that were de-
tected by screening in the two groups, 48% were stage I and II. 
Compared to the USG group, multimodality screening had a 
greater specificity (99.8% vs. 98.2%) and higher PPV (35.1% 
vs. 2.8%) (p＜0.001). The final results are expected in 2015. 
Lu et al.40 performed a single arm, prospective, multicenter 
screening study using the same ROCA in the US and pre-
sented the results at 2010 ASCO Annual Meeting (abstract 
5003). A total of 3,238 participants basically underwent an 
annual CA-125 blood test. Based on the ROCA, they were tri-
aged to the next annual CA-125 (low risk), repeat CA-125 in 
3 months (intermediate risk), or TVS and referral to a gyneco-
logic oncologist (high risk) who made the decision as to 
whether to proceed with surgery. The average annual rates of 
referral in the intermediate risk and high risk groups were 
6.8% and 0.9%, respectively. Eight women subsequently un-
derwent surgery with 3 invasive cancers, 2 borderline and 3 
benign tumors. The combined specificity of ROCA followed 
by TVS for referral to surgery was 99.7% and the PPV was 
37.5%. All 3 invasive cancers were in the early stages (2 Ic and 
1 IIb). The authors concluded that ROCA followed by TVS is 
a feasible screening strategy with excellent specificity and 
PPV in US women with an average risk of ovarian cancer. The 
results are expected to be confirmed by UKCTOCS when the 
final report is released. 
5. Taking a step forward to the origin of ovarian cancer
The early development of ovarian cancer is not completely 
understood. Most studies focused on serous adenocarcinoma, 
the most common histological type of ovarian carcinoma. On 
the other hand, rarer types, such as clear-cell and endome-
trioid, have attracted less attention despite their relative high 
incidence (accounting for 12% of cases in North America and 
even more in Japan),41 and refractoriness to standard plati-
num-based chemotherapy.42 The mechanisms of the trans-
formation of endometriosis into clear cell carcinoma (CCC) 
and endometrioid carcinoma are still unknown, even though 
there is evidence suggesting that both CCC and endometrioid 
carcinoma are associated with endometriosis.43-45
This year, some part of the molecular genetic pathogenesis 
was unveiled by Wiegand et al.46 They found somatic muta-
tions in ARID1A (the AT-rich interactive domain 1A [SWI- 
like] gene) through RNA sequencing of 18 CCC and a CCC 
cell line. ARID1A encodes BAF250a, which participates in the 
chromatin remodeling involved in the regulation of many cel-
lular processes, such as differentiation, proliferation, DNA re-
pair and tumor suppression.47 When they sequenced ARID1A 
in an additional 210 ovarian carcinomas and a second CCC cell 
line, 46% of patients with CCC and 30% of those with endo-
metrioid carcinoma had somatic mutations in ARID1A, 
whereas no ARID1A mutations were found in any of the 76 
high-grade serous carcinomas. Furthermore, immunohisto-
chemical analysis in additional 455 ovarian carcinomas re-
vealed that a loss of ARID1A expression was also specific to 
the subtype and the presence of mutations was strongly corre-
lated with the loss of the BAF250a protein. Interestingly, 
ARID1A mutations and a loss of BAF250a expression were 
evident in the tumor and adjacent atypical endometriosis, but 
not in the distant endometriotic lesions in two patients. This 
suggests that a mutation is an early event in the neoplastic 
transformation from an endometriotic lesion to cancers. 
Considering this study result as well as the nature of the so-
matic mutations in tumors as tumor suppressor genes, all tu-
mor suppressor genes are mutated at a variety of positions 
throughout the coding region of the gene. This holds true for 
mutations in ARID1A, where ARID1A may function as a tu-
mor suppressor gene. 
Even if the clinical application is remote, the possibility that 
ARID1A can trigger a malignant transformation with a muta-
tion and function as a tumor suppressor gene will have a sub-
stantial clinical impact. It may provide a clue not only to gene 
therapy, but also to a prevention strategy in CCC. 
6. Detection and prevention of human papillomavirus 
infection 
Human papillomavirus (HPV) has been a topic over the last 
two years in ‘Major Clinical Research Advances in Gynecolo-
gic Cancer’.1,31 However, there are still many HPV-related is-
sues to be explored. 
The HPV test has higher sensitivity than a cytological test. 
Recent large RCTs demonstrated that the addition of a HPV 
test to the conventional or liquid-based cytology test alone to 
screen women for cervical cancer reduces the incidence of 
high-grade cervical intraepithelial neoplasia (CIN) at the sub-
sequent screening.48-50 Therefore, the HPV test was incor-
porated into the established cervical cancer screening guide-
lines.51
In 2010, there were several confirmative RCTs that com-
pared the efficacy of the HPV test in screening for cervical can-
cer with that of a cytological test.52,53 The study of Ronco et 
al.52 made up for the weak points of previous RCTs,48-50 show-
ing a significant decrease in the incidence of invasive cancer 
and high-grade CIN during a second round of screening com-
pared with the cytological test. Another RCT was a cohort 
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study (PROHTECT) to assess the feasibility and efficacy of of-
fering cervicovaginal lavage self sampling for high risk HPV 
testing to women who do not attend the regular screening 
program. Of the 7,404 women who submitted a self collected 
sample, 7,384 (99.8%) had a valid result and 757 (10.3%) 
were positive for high risk HPV. The study population also 
showed a higher incidence of CIN than the normal regular 
screened population (1.3% vs. 0.8%).54 This study suggested 
a good way of increasing the coverage in a screening program, 
which was as low as 65% of women in the Netherlands in 
2005, because the adjusted compliance rate in the self sam-
pling group was significantly higher than in the control group 
(27.5% vs. 16.6%; p＜0.001). 
The final study we would like to mention in this issue was a 
pooled analysis of 2 RCTs regarding the risk of miscarriage 
with HPV vaccine. Last year, there was a combined analysis of 
five RCTs of pregnancy and infant outcomes in the clinical tri-
als of a quadrivalent HPV vaccine.55 No significant differences 
were noted overall in the proportions of pregnancies resulting 
in live births, fetal loss, or spontaneous abortion between the 
vaccination and placebo groups. However, vaccination is not 
recommended during pregnancy.56 A pooled analysis this year 
confirmed the previous negative causal relationship.57 In this 
study, 26,130 women aged 15-25 were enrolled and random-
ized to 3 doses of bivalent vaccine or hepatitis A vaccine as the 
control. There was no significant increase in miscarriage in 
the women assigned to the HPV vaccine arm, even though 
there was a small increase in the risk of miscarriage (13.7% vs. 
9.1%; p=0.033) in the subgroup of pregnancies conceived 
within the 3 months of vaccination. The authors attributed 
this finding to chance, but could not completely exclude the 
possibility of an increased risk among pregnancies conceived 
within 3 months of vaccination. 
A cost-benefit analysis of the HPV screening test should be 
followed to minimize the costs related to the increased re-
ferral to a colposcopy and overdiagnosis of regressive lesions 
in the young age group.
7. Laparoscopy and laparotomy in endometrial cancer 
staging operation
Although this topic has not been covered at the last two 
December issues, the minimal invasive surgical approaches to 
staging women with endometrial cancer began as early as in 
the 1990s.58-61 Based on these studies, GOG conducted a RCT 
(GOG 2222, LAP2) that compared a laparotomy with laparo-
scopy in the surgical staging of endometrial cancer and re-
ported some of the results last year.62,63 This study revealed 
that laparoscopic comprehensive surgical staging of endo-
metrial cancer could result in less pain, faster recovery, fewer 
postoperative complications, and a shorter hospital stay than 
laparotomy with similar rates of intraoperative complications 
and the ability to identify metastatic disease. In addition, they 
reported a significantly better quality of life (QOL) across 
many parameters in the laparoscopy arm at 6 weeks after 
surgery. However, the significant difference did not last be-
yond 6 months except for the better body image in laparo-
scopy patients. The survival results will be reported when the 
data is established. 
In 2010, there were two RCTs that confirmed the previous 
study results. In 2-stage RCT, the LACE trial, of which the pri-
mary objectives of each stage were the QOL and disease-free 
survival (DFS), the QOL results of stage 1 were reported.64 In 
the QOL substudy, 332 pathologic stage I patients were in-
cluded, 142 in the total abdominal hysterectomy (TAH) group 
and 190 in the total laparoscopic hysterectomy (TLH) group. 
Patients in the TLH group showed greater QOL improve-
ments from surgery at both the early (up to 4 weeks) and late 
(up to 6 months) postoperative recovery periods. Compared 
to the LAP2 trial, in which the QOL difference favoring a lapa-
roscopy was significant only before 6 months after surgery, a 
consistent QOL difference was observed in the LACE trial. 
They suggested three possible explanations. First, the LAP2 
trial required a full pelvic and aortic lymph node dissection 
(LND) in all patients, which resulted in a much higher con-
version rate to a laparotomy than the LACE trial (25.8% vs. 
2.4%). Patients who had received LND had a significantly 
lower functional wellbeing and functional assessment of the 
cancer therapy-general (FACT-G) scores at early recovery 
than those who did not. Furthermore, 52% of the total pa-
tients with fewer patients in the TLH group than TAH group 
underwent a pelvic or aortic LND in the LACE trial (67.6% vs. 
40.5%). Second, the LACE trial aimed to ensure that all sur-
geons were beyond their individual learning curves. Third, all 
procedures in the LACE trial were completed totally lapa-
roscopically, whereas most procedures in the LAP2 trial were 
a laparoscopic-assisted vaginal hysterectomy (LAVH).
Another RCT published in 2010 compared the safety of TAH 
versus TLH.65 This study was performed with 283 patients 
with stage I endometrioid adenocarcinoma or complex atyp-
ical hyperplasia. They concluded that there was no evidence of 
a lower rate of major complications with TLH vs. TAH because 
of the low power for proving equivalence. However, they sug-
gested a benefit for TLH over TAH because of the shorter hos-
pital stay, less pain after surgery, and faster return to daily ac-
tivities, which was in agreement with LAP2. 
Regarding the safety and QOL, laparoscopic approaches are 
comparable to, or even better than a conventional laparotomy 
in the surgical staging of endometrial cancer. However, the 
physician’s preference, conventions of the individual in-
stitutions, and surgeon experience are important factors be-
cause the survival results have not been reported.
8. Internal radiation effectively reduces local recurrence 
of some endometrial cancers: PORTEC-2 trial
PORTEC-1 and GOG 99 showed that pelvic external beam 
radiotherapy (EBRT) significantly reduced the rate of locore-
gional recurrence without an OS improvement in patients 
with high-intermediate risk (HIR) factors: 1) grade 2 or 3, 
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presence of lymphovascular invasion, and outer third my-
ometrial invasion; 2) age 50 or more with any two of the risk 
factors listed above; or 3) age at least 70 with any one risk fac-
tor listed above.66-68 Because approximately 75% of recur-
rences in the control groups were vaginal recurrences in both 
trials, the PORTEC group commenced the subsequent trial, 
PORTEC-2, and published the final results this year.69
The PORTEC-2 trial compared the efficacy and toxicity of 
EBRT and vaginal brachytherapy (VBT) for endometrial can-
cer of HIR. After TAH with a bilateral salpingo-oophorectomy 
with the removal of clinically suspicious pelvic or para-aortic 
lymph nodes, 427 patients with HIR factors were assigned 
randomly to either the EBRT (n=214) or VBT (n=213). The 
primary endpoint was vaginal recurrence. At a median fol-
low-up of 45 months, they estimated the 5-year data (EBRT 
vs. VBT) for vaginal recurrence (1.6% vs. 1.8%; p=0.74), pel-
vic recurrence (0.5% vs. 3.8%; p=0.02), and distant meta-
stases (5.7% vs. 8.3%; p=0.46). Although the OS and DFS 
were similar in the two groups, the rates of acute grade 1-2 
gastrointestinal toxicity at the completion of radiotherapy 
were significantly lower in the VBT group than in the EBRT 
group (12.6% vs. 53.8%).69 Therefore, they concluded that 
VBT should be the adjuvant treatment of choice for patients 
with an endometrial carcinoma of HIR.
While PORTEC-2 showed that VBT was as effective as EBRT 
in ensuring local control with less toxicity, endometrial can-
cer with HIR was likely to metastasize to distant sites, result-
ing in lower survival rates. This drove investigators to in-
corporate chemotherapy into RCTs of adjuvant treatments of 
endometrial cancer with HIR. An ongoing trial, PORTEC-3, is 
comparing concurrent chemoradiation (EBRT with 2 cycles of 
cisplatin in weeks 1 and 4) and adjuvant chemotherapy (4 cy-
cles of carboplatin and paclitaxel at 3-week intervals) with 
pelvic radiation alone in high risk and advanced stage endo-
metrial carcinoma. Another ongoing trial, GOG 249, is a 
phase III trial of EBRT versus VBT followed by paclitax-
el/carboplatin in patients with a high risk of early stage endo-
metrial carcinoma. More knowledge of the strategies that lead 
to better survival of endometrial cancer patients is expected 
through these trials.
9. Extensive lymph node removal in endometrial cancer
The extent of LND was already discussed in ‘Major Clinical 
Research Advances in Gynecologic Cancer 2008’.31 Para-aortic 
lymph nodes (PALNs) at least up to the renal vessels level were 
suggested to be an adequate extent of LND. Although two large 
RCTs failed to show any therapeutic benefits of pelvic LND,70,71 
the therapeutic value of LND in endometrial cancer is still con-
troversial because of the limitations of RCTs, such as short fol-
low-up period, low LN harvest number and exclusion of 
para-aortic LND.72-74
A large retrospective cohort study (SEPAL study) examined 
the survival effect of para-aortic LND in endometrial cancer 
this year.74 Of 671 patients, 325 and 346 were treated with 
pelvic LND and combined pelvic and para-aortic LND, respec-
tively. The primary outcome, OS, was shown to be longer in 
the pelvic and para-aortic LND group than in the pelvic LND 
group (HR, 0.53; 95% CI, 0.38 to 0.76; p=0.0005). However, 
this association was established only in patients with HIR fac-
tors (p=0.0009), not in those with low risk factors. Combined 
pelvic and para-aortic LND added a 10.6% increase in the 5- 
year OS compared to pelvic LND in HIR patients. Multivariate 
analysis showed that in addition to age, tumor type and LN 
metastasis, the type of LND was independently related to 
survival. In other words, combined pelvic and para-aortic 
LND was associated with significantly lower mortality than 
pelvic LND alone. 
The rationale of para-aortic LND in endometrial cancer can 
be found in the literature. More than half of patients with pel-
vic LN metastasis have a PALN metastasis, and 10% of LN 
metastases occur exclusively in the para-aortic region.75,76 The 
para-aortic region also has been shown to be an important site 
of sentinel nodes in endometrial cancer, with 47% of para- 
aortic sentinel nodes and 77% of all PALN metastasis being 
located above the inferior mesenteric artery.75,77
The SEPAL study was not a prospective RCT. However, it 
compensated for the main weakness of ASTEC and Benedetti- 
Panici’s trial, i.e., the exclusion of para-aortic LND from the 
procedure of LND. To change the practice, the conclusion of 
the SEPAL study, i.e., a combination of pelvic and para-aortic 
LND can significantly improve the survival in patients with a 
HIR of recurrence, should be confirmed in a prospective RCT. 
10. Geriatric oncology
Although there was no landmark study in geriatric oncology 
in 2010, there is a rapidly growing interest in this area due 
mainly to the increasing life expectancy, and the increasing 
risk of cancer with age. The proportion of elderly people (older 
than 65) will be between 10 and 30% in most countries, which 
means more than 1 billion worldwide. Furthermore, a quarter 
to a third are expected to develop cancer in some form, i.e., 
250-300 million people.78
Why is it important to focus on geriatric oncology separate 
from general oncology? What is the problem with elderly cancer 
patients? Older people are more vulnerable or frail, and have 
higher prevalence of comorbidity. In addition, they exhibit vari-
able pharmacokinetics/pharmacodynamics of cancer drugs, 
which can result in high rate of toxicity, a decrease in the func-
tional status and a likelihood of developing second cancers.78,79 
This often results in the under-treatment older female ovarian 
cancer patients.80 Older women with ovarian cancer are likely 
to undergo complete debulking surgery less frequently and re-
ceive adjuvant chemotherapy less frequently than their younger 
counterparts, which partly accounts for increased disease-spe-
cific mortality in older patients.81-84 Therefore, there is a good 
reason to select the patients who can endure the toxicity of 
standard chemotherapy as well as stressful extensive surgery. 
Accordingly, considerable effort has been placed into the devel-
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opment of geriatric assessment tools these days.
At the 35th ESMO annual congress, there was an interim 
analysis that evaluated the Groningen Frailty Index (GFI), a 
15-item questionnaire, as a short screening tool to identify pa-
tients in need of a comprehensive geriatric assessment (CGA) 
because the CGA was a time consuming procedure.85 The GFI 
is a useful screening instrument for identifying vulnerable pa-
tients according to the CGA. A two step approach to the initial 
evaluation is becoming a paradigm of choice.78
At this year’s ASCO meeting, two scores for predicting the 
toxicity from chemotherapy were presented. The first one, the 
CRASH score (chemotherapy risk assessment score for high 
age patients), which comprised of grade 4 hematologic and 
grade 3-4 non-hematologic toxicity, was found to offer a vali-
dated, clinically applicable mean of predicting significant dif-
ferences in the risk of severe toxicity.86 The second score, 
which was designed by Hurria et al., developed a risk strat-
ification scheme for grade 3-5 toxicity based on a number of 
risk factors.87 The risk factors for grade 3-5 toxicity included 
age≥73, cancer type (gastrointestinal or genitourinary), 
standard dose, multiple chemotherapeutic agents, falls in the 
last 6 months, assistance with instrumental activities and de-
creased social activity. The percentage incidence of grade 3-5 
toxicity for 1, 2, 3, 4, 5, 6, and 7 risk factors was 23%, 36%, 
50%, 60%, 83%, 90%, and 100%, respectively. However, in-
tegration of these instruments as decision making tools in 
geriatric oncology is needed.78
Apart from the development of geriatric assessment tools, 
more effort to include older patients in prospective RCTs is 
needed to establish a standard therapy for older patients.
11. Chemotherapy in uterine carcinosarcoma 
A recent study revealed that carcinosarcoma (CS), which 
was formerly known as a malignant mixed mullerian tumor, 
might represent metaplastic carcinomas with a sarcomatous 
component being a dedifferentiation of the carcinomatous 
component.88 Based on this histological background of an epi-
thelial origin and the common tumor biological behavior, CS 
and endometrial adenocarcinoma share a similar FIGO stag-
ing system.89,90 However, CSs are definitely more aggressive 
and fatal in a vast majority of cases than endometrial adeno-
carcinomas. The five-year OS is approximately 50%, even in 
stage I CSs, which in contrast to the approximately 80% or 
better in stage I endometrial adenocarcinomas.89 Despite the 
poor prognosis, there have been relatively few trials aimed at 
developing more effective chemotherapeutic regimens due 
mainly to the rarity of CSs.91
Up to a few decades ago, ifosfamide (32%,92 36%93), etoposide 
(7%94), and doxorubicin (10%95) were the most active agents 
in patients with CSs. Since the moderate activity of cisplatin 
(18%) and paclitaxel (18%), which have been used primarily 
for epithelial tumors, such as epithelial ovarian carcinomas or 
endometrial adenocarcinomas, was reported recently,96,97 in-
vestigators have been initiating new trials to evaluate the effi-
cacy and toxicity of those agents in a combination setting in CSs. 
Paclitaxel combined with ifosfamide significantly improved the 
OS in CS compared to ifosfamide alone (13.5 months vs. 8.4 
months; HR, 0.69; 95% CI, 0.49 to 0.97; p=0.03) and the toxi-
cities were as expected and manageable.91 The authors high-
lighted the continuing necessity of new active agents consider-
ing the poor OS.
In accordance with this necessity, another combination of 
paclitaxel and carboplatin was evaluated in a phase II trial by 
the GOG this year.98 Fifty-five patients were enrolled in the 
study, and 46 were evaluated for the antitumor activity and 
toxicity. This regimen was well tolerated with 59% of patients 
completing six or more chemotherapy cycles. The total overall 
response rate was 54% (95% CI, 37 to 67%). Based on these 
promising results, the GOG is now proceeding with a phase III 
non-inferiority trial that is comparing paclitaxel/carboplatin 
with paclitaxel/ifosfamide in CS patients with stage I-IV, re-
current or persistent, measurable or nonmeasurable disease. 
The results of this trial are expected to provide a more effec-
tive chemotherapy strategy for CS.
CONCLUSION
RCT is the best way of changing the major practice guidelines. 
However, it is time consuming in that it generally takes more 
than a decade for a new concept to become a reality in practice, 
particularly when the trial results are unsatisfactory. More 
promising results of RCTs are expected regarding BEV. 
However, it is important to wait for the final report and continue 
to work to maximizing the benefit.
On the other hand, there are many other areas in gynecologic 
oncology that remain to be solved, such as the origin of cancer 
and geriatric oncology. More studies in the future should focus 
on these areas as well as various patient management strategies.
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